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Background/aim: Immunoglobulin G4-related disease (IgG4-RD), is an immune-mediated fibroinflammatory condition, which may
involve multiple organs and mostly presents with high serum IgG4 levels and specific histopathological characteristics. As IgG4-RD is a
relatively new entity the etiology, prevalence and epidemiologic knowledge is quite limited. Although involvement of almost all anatomical
regions has been reported, the most commonly affected regions are pancreas, lacrimal glands, salivary glands, retroperitoneum, orbita,
lymph nodes, kidney and lungs. Diagnosis is made with combined evaluation of clinical, radiological and histopathological findings.
Typical histopathological features include storiform fibrosis, dense lymphoplasmacytic infiltrates and obliterative phlebitis. Its course
is typically marked by remission and relapsing attacks and it may lead to fibrosis, destructive lesions in tissues and organ failure unless
promptly treated. In the treatment of IgG4-RD, many approaches including surgical resection of tissues, systemic glucocorticoids,
steroid-sparing immunosuppressive drugs, and biological agents are employed. Although association is not clear, malignancies are
frequently reported in IgG4-RD patients. Therefore, it is prudent to monitor patients for the symptoms of malignant diseases.
Conclusion: In this review, recent advances in clinico-pathological characteristics, diagnosis, and treatment of IgG4–RD are discussed.
Key words: IgG4-related disease, clinico-pathological characteristics, diagnosis, treatment

1. Introduction
Immunoglobulin G4 related disease (IgG4-RD), is an
immune-mediated fibroinflammatory condition, which
may involve multiple organs and mostly presents with
high serum IgG4 levels and specific histopathological
characteristics. The concept of IgG4-RD was originally
reported by Hamano et al. in 2001 with the rise in serum
IgG4 levels in patients with autoimmune pancreatitis (AIP)
[1]. Its etiology and triggering factors are still unclear. It
occurs most commonly in middle aged and elderly males,
but preponderance of male sex may vary according to
the involve sites. Although involvement of almost all
anatomical regions has been reported, the most commonly
affected regions are pancreas, lacrimal glands, salivary
glands, retroperitoneum, orbita, lymph nodes, kidney and
lungs [2]. IgG4-RD is often recognized incidentally during
radiological or histopathological investigation of a tissue.
Diagnosis is made with combined evaluation of clinical,
radiological and histopathological findings. Its course is
typically marked by remission and relapsing attacks and
it may lead to fibrosis, destructive lesions in tissues and
organ failure unless promptly treated. It also leads to
pressure findings, secondary sclerosis and obstruction

owing to tumefactive lesions [3,4]. In the treatment of
IgG4-RD, many approaches including surgical resection
of tissues, systemic glucocorticoids, steroid-sparing
immunosuppressive drugs, and biological agents are
employed. The spectrum of differential diagnoses includes
malignancies, infections, autoimmune diseases, ANCAassociated vasculitis and Erdheim-Chester disease. In
this review, recent advances in clinico-pathological
characteristics, diagnosis, and treatment of IgG4–RD are
discussed.
1.1. Epidemiology
The precise prevalence of IgG4-RD is not known, due to
being relatively a new entity and largely underrecognized
in clinical practice. The disease occurs mostly in middle
aged and elderly males, peaking between the 5th and
the 7th decade. Studies have shown a male/female ratio
varying between 1.6:1 to 4:1[4].A single study from
Japan, reported a lower male/female ratio, i.e. 1:0.77 [5].
Type-1 AIP (IgG4-related), retroperitoneal fibrosis and
IgG4-related tubulointerstitial nephritis occur more
commonly in males, whereas head and neck involvement
(e.g., thyroiditis, sialadenitis, and dacryoadenitis) is more
common in females [6]. Certain studies revealed higher
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IgG4 serum levels and increased risk of recurrence in men
[6]. In a study, it was observed that patients of Asian origin
had higher IgG4 concentrations than patients of Western
origin. The disease can also occur in pediatric age groups
and shares characteristics with its adult-onset counterpart.
In children, IgG4-RD presents with dacryoadenitis and
mostly as an orbital mass [7].
1.2. Etiology
The exact etiology of IgG4-RD still remains to be elucidated.
However, some susceptibility genes and environmental
factors have been described. Kawa et al. reported that HLADRB1*0405, HLA-DRB1*0401 haplotypes were associated
with
type-1 AIP in Japanese population [8]. As to
Korean population, HLA-DQB1*0202, HLA-DRB1*0701
haplotypes were found to be associated with type 1 AIP
[9]. In a large case-control study, retroperitoneal fibrosis
was found to be associated with HLA-DRB1*03, a marker
of many autoimmune disease [10].
In a few studies, autoantigens such as galectin-3,
laminin 11, and annexin A11 have been reported, the
presence of which, probably causes the triggering of
condition [11–13]. Estrogen is found as a risk factor in
patients with IgG4-related mastitis. Due to eosinophilia in
peripheral blood and involved tissues, an allergic etiology
has also been considered [14]. Atopy/allergy occursin
20%–60% of IgG4-RD patients. A recent study form the
Netherlands found increased occupational substance
exposure among IgG4-RD during their lifetime including
solvents and metal dusts [15]. Finally, an Italian casecontrol study showed asbestos exposure and smoking as
risk factors for retroperitoneal fibrosis [16].
1.3. Histopathological characteristics
Similar pathological features are observed across the
affected tissues [17]. General pathological findings include
dense lymphoplasmacytic infiltrates consisting of IgG4+
plasma cells, storiform fibrosis, obliterative phlebitis and
mild to moderate eosinophilia [17]. The most specific
findingis obliterative phlebitis, complete or partial
obliteration of venous vessels, characterized by infiltration
of vessel wall or lumen with dense lymphoplasmacytic
infiltrate, composed of lymphocytes and plasma cells.
Complete obliteration of the lumen can take place due to
cell accumulation and fibrosis. After obliteration, venous
channels are not visible with standard hematoxylin and
eosin (H&E) stain, hence require specific elastin staining.
Luminal fibrosis without inflammatory cells is not specific
for IgG4-RD and it should suggest other diagnoses such
as organized thrombus. Phlebitis not causing obliteration
may also occur, but it is neither sensitive nor specific for
IgG4-RD. Arterial vessels may also be affected in addition
to venous vessels, but not as severely. Arterial involvement
occurs mostly in cases with lung involvement and
autoimmune pancreatitis but, it is rare in IgG4-RD and its

presence does not rule out the diagnosis [18]. In IgG4-RD,
necrosis, neutrophil-dominant infiltration and granuloma
formation are absent, and if they are present, this is one
of the exclusion criteria according to 2019 classification
criteria [19]. If the above findings are present, a different
accompanying disease such as vasculitis should be
considered. Obliterative phlebitis or storiform fibrosis
are rare in IgG4 associated lacrimal gland, salivary gland,
lymph node and lung involvement, therefore they are
not common features of IgG-RD. Another significant
pathological finding is storiform fibrosis (an irregularly
cartwheel like fibrotic pattern). Collagen fibrils are
interspersed within fibroblasts and myofibroblasts.
Dense lymphoplasmacytic infiltration comprises mature,
immature plasma cells and small lymphocytes (Figures
1A–1D). Lymphocytes are mostly CD4+T lymphocytes
and spread throughout the lesion. B cells are found in
scattered small lymphoid aggregates and ectopic germinal
centers.
In addition, eosinophils are present at mild or moderate
degree and rarely macrophages and histiocytes may be
present. In conditions when eosinophils are preponderant,
eosinophilic angiocentric fibrosis or eosinophilic
cholangitis should be primarily considered. The degree
of fibrosis compatible with IgG4-RD and IgG4 + plasma
cell per high power field (HPF) cut-off number of IgG4
positive cells may vary from tissue to tissue. Although
these numbers have not been verified yet, depending on
the involved organ, cut-off value may range between 10–
200 /HPF. In some organs such as the kidney, 10 IgG4+
/ HPF and in salivary and lacrimal glands, >100 /HPF is
considered as cut-off value. IgG4 /IgG+ plasma cell ratio
provides stronger evidence for the diagnosis of IgG4-RD
than IgG4 +plasma cell number. Cut off value for IgG4+/
IgG+ plasma cell ratio is >40%.
In many neoplasms, increasing number of IgG4+
plasma cells can be found both intratumorally and
peritumorally. InIgG4-RD, plasma cells are polytypic.
Typical electrophoretic pattern of a patient with IgG4RD demonstrates polyclonal hypergammaglobulinemia
with beta gamma bridging. Monotypic plasma cells are
mostly seen inlymphoma and plasma cell malignancies
[20]. A thorough physical examination may reveal the
optimal sites for tissue sampling (i.e. major salivary gland
swelling). Needle biopsies and fine-needle aspiration are
usually inadequate for the diagnosis of IgG4-RD as they
may not be able to detect storiform fibrosis and obliterative
phlebitis. Yet, they may yield enough tissue to reliably
rule out lymphoma and other malignant conditions.
Nevertheless, for a firm diagnosis, pathological findings
should always be supported by clinical, serological and/or
radiological features.

1617

KARADENİZ and VAGLIO / Turk J Med Sci

Figure 1. Characteristic histopathologic features of IgG4-RD. (A–D) IgG4-RD of the lung. (A) Lung parenchyma showing
dense lymphoplasmocytic infiltration with lymphoidfollicles. (B) CD138 positive plasma cells. (C, D) IgG+ positive plasma
cells. (Image courtesy of Nalan AKYÜREK).

1.4. Pathophysiology
IgG4-RD is classified as a fibroinflammatory disorder,
with involvement of both adaptive and innate immune
mechanisms in its pathophysiology. IgG4 accounts for
1%–4% of IgG subtypes [11] and IgG4 antibodies are
specific to mankind. IgG4 antibodies are considered to
have antiinflammatory activity given the fact that they can
undergo Fab-arm exchange and limit immune-complex
formation. Due to the antiinflammatory properties of
IgG4, IgG4 releasing plasmablasts represent a regulatory
response to inflammatory stimuli. In spite of increased
serum IgG4 level and tissue IgG4+plasma cells, which
are characteristic of IgG4-RD, abnormal T cell activity
is considered as the principal immune defect. Most
lymphocytes present in the affected tissues of patients
with IgG4-RD are T lymphocytes. Multiple studies have
showed the involvement of follicular T helper (Tfh)
lymphocytes and CD4+ cytotoxic T lymphocytes (CTL)
in the pathogenesis of the disease [21]. It was observed
that Tfh cells increase in affected tissues and peripheral
blood of patients. In some studies, it was observed that
IgG4-RD associated Tfh cells, induce differentiation and
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proliferation of B cells at a higher degree than normal Tfh
cells in tissues [22]. Studies on subtypes of Tfh cells have
indicated that,cells without CXCR3 and CCR6 expression,
release Th2 type cytokines (IL-4,IL-5,IL-13) [23]. IL-4,
a Tfh cytokine, induces germinal center development,
B cell differentiation, plasmablast induction and class
switch recombination, culminating in IgG4 production
[24]. Many studies have demonstrated that progression
of fibrosis is maintained via IL-4, IL-5, IL-13 cytokines
[25]. IL-5 and IL-13 increase IgE and IgG4 production
and lead to eosinophilic infiltration. In AIP, an increase
in CD4+CD25+ Treg cells was found [26]. Treg cells
contributeto IgG4 class switching and fibrosis respectively
by releasing IL-10 and TGF-B [27]. Recent studies have
stressed the importance of CD4+ CTL T lymphocytes
in the physiopathology of the disease [28]. Matto et al.
demonstrated oligoclonal expansion of CD4+ effector /
memory CTL cells in both blood and tissues of IgG4RD patients [29]. These CTL T cells contribute to the
development of fibrosis in association with the mediators
they release such as granzyme A, perforin, interleukin-1
β (IL-1 β), transforming growth factor -beta (TGF-β)
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and interferon-gamma (IFN-γ). Besides, cytotoxic T
cells express F7 (SLAMF7) molecule on their surface,
which contributes to fibrosis and is not present in other
T cells. [28]. In patients with active IgG4-RD, rituximab
leads to reduction in CD4+CTL cells secondary to B cell
depletion [29]. In addition to T cells IgG4+ hypermutated
plasmablasts have also been described in the blood of
patients with active IgG4-RD [30].
2. IgG4-related disease and clinical findings
IgG4-RD is usually a systemic disease, but a recent
cluster analysis identified the following main phenotypes:
pancreato-hepato-biliary disease, retroperitoneal fibrosis
and/or aortitis, head and neck limited disease, classical
Mikulicz syndrome with systemic involvement [31]. The
main organ manifestations are discussed below.
2.1. IgG4-related lymphadenopathy
Although lymphadenopathy usually occurs in conjunction
with other clinical and laboratory findings of the disease,
sometimes it may be the initial or sole finding. There
are 5 histological patterns and nodal inflammatory
pseudotumor-like represents the most specific pattern for
IgG4-RD (Table 1). Lymph nodes are usually, nontender
and have elastic consistency. Symptoms usually emerge
due to mass effect by enlarged lymph nodes. Usually,
more than one lymph node group is affected. Mediastinal,
hilar, intraabdominal and axillary lymph nodes are the
most commonly involved. As storiform fibrosis, one
of the characteristic features of IgG4-RD, occurs rarely
and IgG4 plasma cells stain positive in many diseases,
making diagnosis solely with lymph node biopsy is quite
challenging. While a true lymphadenitis is characterized
by the presence of IgG4+ plasma cells in interfollicular
regions, their presence in intrafollicular regions is
nonspecific. The differential diagnosis of generalized
lymphadenopathy includes sarcoidosis, multicentric
Castleman disease, infections (e.g., tuberculosis, HIV
infection), lymphoma and other malignant conditions.
IgG4 related lymphadenopathy is distinguished from other
lymphadenopathies by its mild lymph node enlargement,
typical characteristics in biopsy, absence of constitutional
symptoms, and response to glucocorticoids [32].
2.2. IgG4-related pancreatitis
There are two types of autoimmune pancreatitis (AIP).
The IgG4-RD associated AIP is called as type 1 AIP,
while the IgG4-unrelated AIP is type 2 AIP or idiopathic
duct-centric chronic pancreatitis (IDCP) or granulocytepositive epithelial pancreatitis. Type 2 AIP occurs much
more rarely than type 1 AIP and is sometimes associated
with inflammatory bowel disease. Types 1 and 2 AIP
display different clinical features. Type 1 AIP occurs
mostly in elderly males and is less likely to cause jaundice
and abdominal pain. Type 2 AIP affects mostly younger

Table 1. IgG4-related lymphadenopathy histological patterns.
(i) Multicentric Castleman disease-like
(ii) Follicular hyperplasia
(iii) Interfollicular expansion
(iv) Progressive transformation of germinal center-like
(v) Nodal inflammatory pseudotumor-like

people without any sex predilection. In addition, its rate
of recurrence is lower and is confined to the pancreas.
In the majority of type 1 AIP patients, extrapancreatic
IgG4-RD involvement occurs. Development of endocrine
and exocrine pancreatic insufficiency manifesting
with hyperglycemia and steatorrhea is not uncommon
among patients who suffer from wither type of AIPs. In
some patients with type 1 AIP, acute recurrent chronic
pancreatitis may occur. Type 1 AIP may imitate pancreatic
carcinoma as it leads to mass-like lesions of the pancreas. It
is also difficult to clinically discriminate AIP patients from
those with adenocarcinoma since painless obstructive
jaundice and high serum IgG4 concentrations may be
seen in both conditions [33]. Many AIP patients had to
undergo radical surgery due to concern about pancreatic
cancer. In CT images of type 1 AIP patients, enlarged
pancreas, sausage-like pancreas, loss of lobulation,
irregular pancreatic duct, hypodense rim/halo sign (edema
surrounding the organ in the form of halo) and minimal
peripancreatic fat stranding are observed. Magnetic
resonance cholangiopancreatography (MRCP) images
of patients with IgG4 autoimmune pancreatitis show
nonvisualization of a long segment of the main pancreatic
duct. Patients who are left untreated or have long term
AIP can develop symptoms of chronic pancreatitis with
atrophic pancreas and intraductal calcifications on
imaging [34].
2.3. IgG4-related sclerosing cholangitis (IgG4-RSC)
IgG4-RSC usually produces obstructive jaundice,
weight loss and/or steatorrhea and elevation in hepatic
function tests [35]. IgG4-RSC is different from primary
sclerosing cholangitis (PSC) which occurs at younger
ages in association with inflammatory bowel disease
and histopathologic examination shows circumferential
or onion-skin like fibrosis and in advanced stages,
ductopenia [36]. Unlike PSC, IgG4-RSC tissue biopsy
yields IgG4 + plasma cell infiltrates, severe interstitial
fibrosis, transmural thickening and more severe portal and
lobular inflammation [36]. Other differences are increased
serum IgG4 concentration and characteristic response
to corticosteroids. IgG4-RSC is the most common extra
pancreatic disease in patients with type 1AIP, with a
prevalence of 70%. It seldomly appears in the absence of
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pancreatitis. Considering the difficulties in making the
diagnosis of isolated IgG4-RSC in the biliary system, it is
not easy to estimate its actual prevalence and to appreciate
its severity [37]. IgG4-RSC can also be confused with
cholangiocarcinoma, but the latter has higher serum
bilirubin and CA19-9 levels [38]. CT findings of IgG4-RSC
include multiple focused strictures, >2.5 mm thickening in
bladder wall, and long segment narrowing. These strictures
are smooth in morphology, with resultant proximal
biliary tree dilatation. Posttreatment imaging may reveal
radiologic improvements in strictures and biliary tree wall
thickening [39].
2.4. IgG4-related salivary gland involvement
The involvement of major salivary (parotid and
submandibular) glands is a common feature of IgG4RD. Lacrimal or parotid gland enlargements, which was
previously termed as Mikulicz syndrome, and Küttner
tumor (chronic sclerosing sialadenitis) have been
incorporated into IgG4-RD context [40]. In IgG4-RD,
lacrimal gland, parotid gland and submandibular gland
are usually involved together at different combinations.
Although it is not always symmetrical, glands are
usually involved bilaterally. Renal involvement with low
complement levels might be encountered in this condition
[4].
In the morphology of IgG4-related sialadenitis,
fibroinflammatory infiltration occurs in interlobular
septa, but lobular architecture is preserved, and commonly
hyperplastic irregular lymphoid follicles are detected [41].
In some sialadenitis cases due to stones, IgG4 positive
cells may be present. In a study, serum IgG4 levels were
found elevated in 7.5% of patients with primary Sjögren
syndrome (pSS). Compared to pSS, in IgG4-RD have
higher serum IgG4 levels and negative antinuclear, antiRo/SSA and anti-La/SSB antibodies [42]. Radiologically,
pSS demonstrates the “apple-tree sign” on sialography,
indicative of contrast spilling from degenerated glands.
Both pSS and IgG4-RD enlarge lacrimal and salivary
glands, but dryness in mouth and eyes is milder in IgG4RD and more severe in pSS due to more extensive epithelial
cell apoptosis. Upon immunosuppressive treatment IgG4RD patients regain their salivary functions whereas, pSS
often leads to irreversible destruction of salivary units.
2.5. IgG4-related dacryoadenitis and orbital inflammatory
disease
IgG4-RD presenting with the involvement of lacrimal
glands (IgG4-related dacryoadenitis) [43] and orbital
involvement occurs at the rate of 17%–23% [44]. IgG4
related orbital inflammatory disease commonly involves
lacrimal glands, while involvement of orbital soft
tissue (IgG4-related sclerosing orbital inflammation),
extraocular muscles, palpebrae, optical nerve, or orbital
bone have also been reported. Approximately 70%–80%
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of patients have extra ophthalmic findings. Some studies
have suggested that it is more common in females [45],
whereas some other studies reported that it is more
common in males [46]. Patients may present with
symptoms of exophthalmos, periocular swelling and mass
which can lead to proptosis and compression of local
nerves. IgG4 related dacryoadenitis may lead to blindness
unless treatment is rapidly commenced [47]. Fibrosis
occurs mostly in interlobular septa and causes impairment
of the architecture of lacrimal gland [48]. The differential
diagnosis of IgG4 related orbital disease includes Sjögren’s
syndrome, granulomatosis with polyangiitis, sarcoidosis,
lymphoma, infection, orbital pseudotumor and idiopathic
orbital inflammation [48] (Table 2). IgG4-RD accounts for
25%–50% of orbital pseudotumor. In addition, depending
on diagnostic criteria used, it also accounts for 5%–25%
of idiopathic orbital inflammations [49]. In a study,
38 patients diagnosed with chronic dacryoadenitis or
orbital pseudotumor, 15(39%) met the definite criteria
of IgG4-RD, while 5 patients had probable disease [50].
Some other studies have demonstrated that IgG4-RD
itself, produces susceptibility to ocular adnexal mucosa
associated lymphoid tissue (MALT) lymphoma and other
lymphomas [51].
2.6. Retroperitoneal fibrosis and related diseases
Retroperitoneal fibrosis (RPF) is one of the most commonly
encountered subtypes of IgG4-RD. RPF may be idiopathic
(Ormond disease) or may have a secondary cause (Table
3). Idiopathic forms account for 70% of cases and may
be of IgG4-RD or non-IgG4-RD origin. In a study, it was
established that IgG4-RD was responsible for many of RPF
cases, which were previously considered idiopathic [52].
Asbestosis and tobacco exposure increase RPF risk [16].
Patients usually present with urinary obstruction and
kidney failure and frequently complain of lower back, flank
and abdominal pain due to urinary obstruction [53]. In
two large retrospective studies, pain was evident in more
than 90% of patients on presentation [54,55]. Pain is dull
and not well localized and does not change with activity or
body position. Sometimes, the pain may be acute/sharp
resembling that of a renal colic. In a study performed
in North America, many cases of retroperitoneal
fibrosis were identified during radiologic examinations
performed for the suspicion of nephrolithiasis [56]. Due
to inflammatory nature of lesion, pain responds better
to NSAIDS than opioids. In a study conducted on 40
patients, testicular pain was reported in more than 50%
of male patients [57]. Kidney atrophy may be seen as a
result of unilateral chronic obstructive uropathy or renal
artery stenosis caused by RPF. Patients may exhibit edema,
thrombophlebitis or deep vein thrombosis in lower
limbs due to obstruction of inferior vena cava. In a study
conducted in Netherlands, hydrocele was detected in 29%
of patients [55]. Serum creatinine and urea levels may
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Table 2. Differential diagnosis of IgG4-related disease.
Autoimmune disorders
-Rheumatic conditions
Sarcoidosis
Sjogren’s syndrome
ANCA-associated vasculitis
-Granulomatosis with polyangiitis
-Eosinophilic granulomatosis with polyangiitis
-Microscopic polyangiitis
Takayasu’s arteritis-giant cell arteritis
Behçet disease
-Nonrheumatic conditions
Primary biliary cirrhosis-primary sclerosing cholangitis
Autoimmune hepatitis
Hashimoto’s thyroiditis
Castleman’s disease
Lymhomatoid granulomatosis

Infections
Bacterial
Viral
Mycobacterial
Spirochetal
Fungi
Lymphoproliferative disorders
MALT lymphoma with plasmocytic differentiation
Plasma cell neoplasia
Follicular lymphomas

Systemic inflammatory disorders
Rosai-Dorfman disease
Multicentric Castleman disease
Chronic sialadenitis
Type 2 AIP
Inflammatory bowel disease
Erdheim-Chester disease

Tumors
Inflammatory myofibroblastic tumor
Adenocarcinoma and squamous cell carcinoma
Eosinophilic disorders
Eosinophilic angiocentric fibrosisKimura
diseaseAnjiolymphoid hyperplasia with eosinophilia

Table 3. Main causes o secondary retroperitoneal fibrosis.
Drugs

Malignancy

Infections

Ergot derivatives

· Carcinoid tumor

· Tuberculosis

· beta blockers,

· Hodgkin’s lymphoma

· Histoplasmosis

· bromocriptine,

· Non-Hodgkin’s lymphoma

· Actinomycosis

· hydralazine,

· Retroperitoneal sarcoma

· methysergide,

· Breast cancer

Histiocytosis (Erdheim-Chester disease)

· Biologicals

· Colorectum cancer

Secondary (AA) amyloidosis

-etanercept

· Prostate cancer

Radiation therapy

-infliximab

· Bladder cancer

Surgery/trauma

rise secondary to urinary obstruction. High acute phase
reactants are usually associated with a more symptomatic
disease however they respond poorly to treatment and
usually do not increase during flares. The initial imaging
modality employed for investigating urinary pathologies
is ultrasonography [58]. For visualization of pancreas and
retroperitoneal organs CT or MRI is preferred. Histological
confirmation of RPF may be required if the mass lesion has
atypical localization, and clinical and laboratory findings
suggestive of infection or malignancies. During surgical
exploration, macroscopically, a hard, white plaque of

varying thickness is seen. Microscopically, fibrous tissue
contains extracellular matrix which is organized in thick
irregular bundles composed of type 1 collagen fibrils
surrounding small retroperitoneal vessels [59] (Figures
2A–2C).
Typical CT findings, include medially displacement
of ureter due to compressive effects of fibroinflammatory
mass lesion involving surroundings of aorta and inferior
vena cava18-FDG positron emission Tomography (18FDG PET) is a beneficial and reliable technique for
evaluating metabolic or inflammatory activity of disease.
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Serious complications such as renal failure may occur
unless patients are treated promptly [60] (Figures 3A–3E).
The aim of treatment is to relieve obstruction caused
by fibrosis, to halt progression of the fibrotic process and
to prevent disease recurrence. If there is an important
urinary tract obstruction, this should be eliminated with
open surgery, percutaneous intervention or endoureteral
approach. As soon as diagnosis is made (the same day
as urological intervention) steroid treatment should be
commenced. If there is no adequate response to steroids
following approximately four weeks of treatment,
immunosuppressive treatments should be instituted such
as mycophenolate mofetil (MMF), azathioprine (AZA),
methotrexate, cyclophosphamide, and cyclosporine [61].
Patients who have positive PET findings at the onset of
treatment respond better to steroids than those who have
negative PET findings [62]. If clinical or radiological
improvement is not observed in spite of four weeks of

medical treatment, repeat CT investigation and biopsy are
recommended in order to corroborate the diagnosis.
2.7. IgG4-related renal involvement
IgG4-related renal involvement, most commonly occurs as
tubulointerstitial nephritis (TIN). IgG4-related TIN may be
detected during investigations carried out for the suspicion
of kidney masses, abnormal urinary analysis, and/or renal
failure. Histological findings include lymphoplasmacytic
infiltration of the renal interstitium, tubular atrophy and
fibrosis. In patients with IgG4-related TIN, low C3 and C4
levels, can be seen especially in patients with active disease.
The cause of hypocomplementemia occurring in IgG4TIN is not entirely clear, since IgG4 itself binds weakly
to complement. Hence, it is thought that IgG1 and IgG3
account for hypocomplementemia. CT imaging shows
enlarged kidneys and hypodense lesions. Apart from IgG4TIN, membranous nephropathy and mesengioproliferative
glomerulonephritis may also occur, albeit rare in IgG4-

Figure 2. Characteristic histopathologic features of IgG4-RD. (A–C) IgG4-RD of the omentum. (A) Omental biopsy showing fat
necrosis areas and peripherally located dense lymphoplasmocytic infiltrate. (B) Higher power view of dense lymphoplasmocytic
infiltrate. (C) IgG4 positive plasma cells in one high power field. (Image courtesy of Nalan AKYÜREK).

Figure 3. PET findings in RPF. 18F-FDG PET scans in a patient with idiopathic RPF show intense accumulation of 18F-FDG
arround the abdominal aorta [A, axial CT, B, axial PET, C, axial fusion images, D, coronal fusion images, E, coronal maximum
intensity projection (MİP) PET images)]. (Image courtesy of Özlem ATAY).
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related kidney disease [63]. Membranous nephropathy can
be concurrent with TIN and presents with nephrotic range
proteinuria and hypoalbuminemia [63].
2.8. IgG4-related respiratory disease (IgG4-RRD)
IgG4-RRD may be detected incidentally with symptoms
such as cough, dyspnea, and chest pain. Apart from
dense lymphoplasmacytic infiltrates, small aggregates of
neutrophils may be present in alveolar spaces or within
the inflammatory infiltrates.The fibroinflammatory
infiltrate typically extends towards perilymphatic regionbronchovascular tree and interlobular septa.
Lung manifestations predominantly present as
inflammatory pseudotumor, interstitial pneumonitis,
organizing pneumonia, and lymphomatoid granulomatosis.
IgG4-RD involves not only lung parenchyma, but also
pleura, airways, mediastinum, and vasculature. There are
four patterns of lung involvement [64] (Table 4).
Delayed diagnosis and treatment of IgG4-related
interstitial pneumonia can lead to significant pulmonary
fibrosis. Many patients exhibit more than one pattern.
Visceral and parietal pleura thickening may also take
place. In a recently published case-based review, IgG4related pleural effusion has been reported in 17 patients
and in pleural effusion sampling, adenosine deaminase
levels were found to be high [65]. The differential
diagnosis of IgG4-RRD include MCD, sarcoidosis,
lymphoma and inflammatory myrofibroblastic tumor.
The solid nodular type may be confused with sarcoidosis.
Hilar lymphadenopathy is present in both sarcoidosis and
IgG4-RD and they might be discriminated by PET CT,
since CT alone is inadequate in this respect. In sarcoidosis
fluorodeoxyglucose SUV max uptake on PET is higher.
Ga-67 scintigraphy is inadequate in staging of the disease
and evaluation of activity and response to treatment in
comparison to PET CT [66].
In IgG4-RRD, the relation with malignancy depends
on the pattern displayed, i.e. while the risk of malignancy
is higher in those with interstitial and nodular patterns,
it is not seen in those with bronchovascular pattern. In
addition, prognosis is poorer in interstitial pattern.
2.9. IgG4-related aortitis/periaortitis
IgG4-RD is one of the causes of noninfective aortitis [67].
In retrospective pathological studies of patients undergoing
aorta resection, a number of patients with thoracic

lymphoplasmacytic aortitis, abdominal periaortitis and
inflammatory abdominal aorta aneurysm were identified
[68] (Figures 4A and 4B).Thoracic aortitis can lead to
aneurysm formation or dissection, though it is often
asymptomatic and detected incidentally by imaging. In a
recent prospective study, in 89 out of 587 IgG4-RD patients
(15.2%), periaortitis/periarteritis was detected, which was
most commonly distributed in infrarenal abdominal aorta
and iliac arteries. (83.5%) [69]. IgG4-RD may also involve
medium sized vessels such as coronary arteries in addition
to large vessels. CT angiography is observed the soft-tissue
masses around the proximal segments of the left anterior
descending (LAD) and right coronary artery (RCA). The
presence “mistletoe sign” in CT angiography is an indicator
of IgG4-RD associated coronary artery disease [70].
Mistletoe is a plant attached to the branches of a tree, similar
to the perivascular soft, tissue attached to the coronary tree.
2.10.
IgG4-related thyroid disease
Riedel thyroiditis, which is a rare form of thyroiditis, is the
IgG4-RD of thyroid gland. Stiff thyroid leads to dyspnea,
dysphagia and hoarseness. Cytologic examination is not
always diagnostic and diagnosis is usually made with
thyroid resection, carried out to relieve clinical symptoms
and to rule out malignancy. The fibrosing variant of
Hashimoto thyroiditis has also been associated with IgG4RD [71]. In comparison to IgG4-negative thyroiditis, IgG4RD thyroiditis presents serologically with higher levels of
antithyroglobulin and antithyroid peroxidase antibodies.
2.11. Other IgG4-related organ involvements
Skin disease (cutaneous pseudolymphoma, hyperplasia
with eosinophilia, angiolymphoid hyperplasia with
eosinophilia (ALHE)):
IgG4-RD should be considered as part of the differential
diagnosis for nodules, papules, and plaques. Cutaneous
lesions are predominantly located on the head and neck
in IgG4-RD cases (73.1%) [72]. IgG4-related autoimmune
hepatitis and hepatic inflammatory pseudotumor,
constrictive pericarditis, sclerosing mastitis, gastritis are
included among the rare IgG4-RD manifestations.
3. Diagnosis
The diagnosis of IgG4-RD is currently based on the
comprehensive classification criteria proposed in 2019 by
Wallace et al. [19] (Table 5).

Table 4. IgG4-related respiratory disease histological patterns.
(i) Solid nodular pattern			

Obliterative arteritis is often seen

(ii) Broncho vascular pattern			

Thickening of interlobular septa and bronchovascular bundles

(iii) Alveolar interstitial pattern		

Honeycombing, bronchiectasis, and widespread ground glass

(iv) Round-shaped ground glass opacity
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Figure 4. A and B, retroperitoneal fibrosis. Contrast-enhanced axial images (A) and coronal image (B) of computed tomography
of the abdomen show heterogenous soft tissue densities surrounding aorta in the retroperitoneum at the infrarenal level. Soft
tissue densities severely surround aorta, aortic bifurcation and main iliac arteries bilaterally (black arrow). (Image courtesy of
Emetullah CİNDİL).

Comprehensive classification criteria issued by 2019
ACR/EULAR involves three steps; in the first step, in a
potential case, at least one of the 11 organs consistent with
the definition of IgG4-RD should be demonstrated. In the
second step, the exclusion criteria step, a total of 32 clinical,
serological, radiological and pathological items should be
considered. The presence of one of these criteria is enough
to rule out IgG4-RD. In third step, 8 important criteria are
considered, and serological results, radiological evaluations
and pathological interpretations are addressed, scored and
interpreted. Overall a score of 20 or more is diagnostic of
IgG4-RD. Although comprehensive diagnostic criteria are
commonly used, as it is difficult to take biopsy from regions
such as pancreas, retroperitoneum and orbita, they can
be used with difficulty in diseases of these regions. Thus,
organ specific diagnostic criteria have been developed
and can be employed instead of comprehensive diagnostic
criteria [73,74].
3.1. Laboratory parameters
In many patients, serum IgG4 levels are high. Its level
usually correlates with the severity of the disease. However,
serum and tissue IgG4 concentrations are neither specific
nor sensitive indicator of IgG4-RD. A study demonstrated
that almost half of active patients with histologically proven
IgG4-RD had normal serum IgG4 levels [4]. Involvement
of certain organs or anatomic regions, particularly the
retroperitoneum, have lower rates of correlation with
serum IgG4 levels. False-negative IgG4 levels due to the
prozone phenomenon should be considered in cases
with multiorgan involvement and low serum IgG4. In
addition, peripheral eosinophilia, high serum IgE levels,
polyclonal hypergammaglobulinemia, high CRP, low
titer positive antinuclear antibody, rheumatoid factor
and hypocomplementemia are common in IgG4-RD. The
serum IgG4 level decreases promptly after treatment with
glucocorticoids or B cell depletion in most patients despite
many patients do not achieve normal levels while they are
in clinical remission. In a prospective trial of rituximab in
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IgG4-RD, higher baseline levels in serum IgG4, IgE and
blood eosinophil concentrations predicted greater risk of
IgG4-RD relapse and shorter time to relapse, rendering
monitoring of these values significant [75]. Apart from
IgG4,in a recent study, in the sera of 28 IgG4-RD patients,
thymus and activation-regulated chemokine (TARC)
levels were measured and were found to be higher than
those of patients with Sjögren syndrome and control
group. In addition, it was established that they were related
to responder index and organ involvement and that TARC
stimulated plasmablasts in vitro [76]. Serum plasmablast
concentration is a more sensitive marker for the diagnosis
of IgG4-RD compared to the serum IgG4 level, however,
due to the difficulty of application, it has limited clinical
use.
4. Treatment
In IgG4-RD, there is a risk of progression from
inflammatory and proliferative stage which is responsive
to treatments, to fibrotic stage responding weakly to
treatments causing severe organ damage. Early diagnosis
and treatment are important owing to irreversible organ
damage. The aim of treatment is to minimize adverse
effects with glucocorticoids and other agents, to produce
remission of disease and to preserve organ function. After
diagnosis is made, pretreatment evaluation should be made
for assessing severity and extension. Routine laboratory
tests, whole blood count, kidney and liver function tests,
biochemical parameters including amylase and lipase,
levels of IgG subtypes, IgE concentration, serum C3 and
C4 concentrations, urinalysis (asymptomatic proteinuria
may be an indicator of TIN), chest, abdominal and pelvic
CT or MRI and PET (for determining the extension of
disease) may be ordered. In patients with asymptomatic
lymphadenopathy, slight salivary gland enlargement, and
incidentally detected lung nodules, watchful waiting policy
is recommended. These patients should be evaluated every
six months. Patients with symptomatic active IgG4-RD
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require treatment. Disease activity may be determined by
laboratory and imaging methods in addition to symptoms,
for example in patients with lacrimal gland swelling,
orbital pseudotumor or proptosis. Urgent treatment may
be warranted in some patients with pancreatobiliary or
renal disease. In addition, patients with aortitis (due to
risk of aneurysmal complications such as rupture), RPF
(dueto renal failure secondary to ureteral obstruction)
pachymeningitis (due to neurological deficit risk), AIP
(due to exocrine and endocrine failure) and pericarditis
(due to risk of cardiac tamponade) should be urgently
treated. In asymptomatic patients with radiological and
laboratory findings in vital organs, (e.g., asymptomatic
IgG4-RD aortitis/periaortitis, IgG4-RD retroperitoneal
fibrosis) treatment should be initiated, since irreversible
sequelae may develop [77]. Glucocorticoids are first

line agents for remission-induction in treatment naive
patients unless they are contraindicated.
Initially,
prednisone monotherapy is recommended at the dose
of 0.6 mg/kg/day (typically 30–40 mg /day). Almost all
patients respond to 40 mg daily prednisone within 2–4
weeks. Many patients respond even earlier. After clinical
response is obtained at the involved organ, prednisone
dose may be gradually tapered during 3–6 months until
it is completely discontinued. Rheumatologists from Asia
prefer to maintain low dose glucocorticoids (2.5–5mg/
day) for three years [78]. Symptomatic improvement
upon response to glucocorticoids manifests with decrease
in the size of mass or organ enlargement, improvement
in organ functions and reduction in serum IgG4 levels.
It has been observed that after glucocorticoid induction
treatment, CD4 +T cells decline [79]. Recurrence was

Table 5. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4- RD
[Wallace ZS et al. (2019)].
Step 1: Entry criteria (Yes† or No)

Step 2: Exclusion criteria:domains and items ‡ (Yes or No δ)

Characteristic*clinical or radiological involvement
of a typical organ (e.g., pancreas, salivary glands, bile
ducts, orbits, kidney, lung, aorta, retroperitoneum)
orpathological evidence of an inflammatory process
accompanied by a lymphoplasma cyticin filtrate of
uncertain aetiology in one of these same organs.

Clinical
· Fever
· No objectiveresponsetoglucocorticoids
Serological
· Leucopenia and thrombocytopenia with no explanation
· Peripheral eosinophilia
· Positive antineutrophilcyto plasmic antibody (specifically aganist
proteinase 3 or myeloperoxidase)
· Positive SSA/Ro or SSB/La antibody
· Positive double-stranded DNA, RNP or Sm antibody
· Other disease-specific autoantibody
· Cryoglobulinemia
Radiological
· Known radiological findings suspicious for malignancy or infection that
have not been sufficiently investigated
Rapid radiological progression
Long bone abnormalities consistent with Erdheim-Chester disease
Splenomegaly
Pathological
· Cellular infiltrates suggesting malignancy that have not been sufficiently
evaluated
· Markers consistent with inflammatory myofibroblastic tumour
· Prominent neutrophilic inflammation
· Necrotizing vasculitis
· Prominent necrosis
· Primarily granulomatous inflammation
· Pathologic features of macrophage/histiocytic disorder
· Known diagnosis of the following:
Multicentric Castleman’s disease
Chrohn’s disease or ulcerative colitis (if only pancreatobiliary disease is
present)
Hashimoto thyroiditis (if only the thyroid is affected
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Table 5. (Continued).
If case meets entry criteria and does not meet any exclusion
criteriaproceed to Step 3 ¶

Step 4: Total inclusion points

Step 3. Inclusion criteria: domains and items		
Numerical weight
Serum IgG4 concentration
· Normal or not checked				
0
· >Normal but <2x upper limit of normal			
+4
· 2-5x upper limit of normal				
+6
· ≥5x upper limit of normal				
+11
Bilateral lacrimal, parotid, sublingual and submandibular glands
· Not set of glands involved				
0
· One set of glands involved				
+6
· Two or more sets of glands involved			
+14
Chest
· Not checked or neither of the items listed is present		
0
· Peribronchovascular and septal thickening			
+4
· Paravertebral band-like soft tissue in the thorax		
+10
Pancreas and biliary tree
· Not checked or neither of the items listed is present		
0
· Diffuse pancreas englargement (loss of lobulations)		
+8
· Diffuse pancreas englargement and capsule-like rim		
+11
with decreased enhancement
· Pancreas (either of above) and biliary tree involvement		
+19
Kidney
· Not checked or neither of the items listed is present		
0
· Hypocomplementemia				+6
· Renal pelvis thickening/soft tissue			
+8
· Bilateral renal cortex low-density areas			
+10
Retroperitoneum
· Not checked or neither of the items listed is present		
0
· Diffuse thickening of the abdominal aortic wall		
+4
· Circumferential or anterolateral soft tissue around		
+8
the infrarenal aorta or iliac arteries
Histopathology
· Uninformative biopsy				0
· Dense lymphocytic infiltrate				
+4
· Dense lymphocytic infiltrate and obliterative phlebitis		
+6
· Dense lymphocytic infiltrate and storiform fibrosis		
+13
with or without obliterative phlebitis
Immunostaining **
0–16, as follows:
· Assigned weight is 0 if: the IgG4+/IgG+ratio is 0%–40% or indeterminate and the number of
IgG4+cells/hpf is 0–9 ***
· Assigned weight is 7 if: (1) the IgG4+/IgG+ ratio is ≥41% and the number of IgG4+cells/hpf is
0–9 or indeterminate or (2) the IgG4+/IgG+ ratio is 0%–40% or indeterminate and the number of
IgG4+cells/hpf is ≥10 or indeterminate.
· Assigned weight is 14 if: (1) the IgG4+/IgG+ ratio is 41%–70% and the number of IgG4+cells/hpf is
≥10 or (2) the IgG4+/IgG+ ratio is ≥71% and the number of IgG4+ cells/hpf is 10–50.
Assigned weight is 16 if: the IgG4+/IgG+ratio is ≥71% and the number of IgG4+cells/hpf is ≥51.

A case meets the classification criteria for
IgG4-RD if the entry criteria are met, no
exclusion criteria are present, and the total
points is ≥20.

*Refers to enlargement or tumour-like mass in an affected organ except in (1) the bile ducts, where narrowing tends to occur, (2) the
aorta, where wall thickening or aneurysmal dilatation is typical and (3) the lungs, where thickening of the bronchovascular bundles is
common.
†If entry criteria are not fulfilled, the patient cannot be further considered for classification as having IgG4-RD.
‡Assessment for the presence of exclusion criteria should be individualised depending on a patient’s clinical scenario.
δ If exclusion criteria are met the patient cannot be further considered for classification as having IgG4-RD.
¶ Only the highest weighted item in each domain is scored.
**Biopsies from lymph nodes, mucosal surfaces of the gastointestinal tract and skin are not acceptable for use in weighting the
immunostaining domain.
*** ‘Indeterminate’ refers to a situation in which the pathologist is unable to clearly quantify the number of positively staining cells
within an infiltrate, yet can still ascertain that the number of cells is at least 10/hpf. For a number of reasons, most often pertaining to
the quality of the immunostain pathologist Are sometimes unable to count the number of IgG4+ plasma cells with precision yet even so,
can be confident in grouping cases into the appropriate immunostaining result category. hpf: high power field, IgG4-RD: IgG4-related
disease.
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observed in 46% of IgG4-RD patients during and after
the tapering of the steroid dose [80]. In selected highrisk patients, i.e. those who have high serum IgG4, IGE
and eosinophilia at the onset, those with multiple organ
involvement and previous history of relapse, remission
maintenance treatment should be contemplated [81]. In
a recent retrospective study performed with 277 IgG4RD patients, recurrence was observed more frequently
in patients diagnosed at early ages, those who had allergy
history and whose treatment was instituted long time
after the diagnosis. Cumulative relapse rates were found
to be12.86%, 27.84%, and 36.1%, respectively at 12, 24,
and 36 months. As to organs affected by recurrence, (125
organs, 101 patients) recurrence was in de novo organ in
40 patients and in the same organ in 85 patients. The most
common de novo recurrence occurred in parathyroid
gland. Regarding recurrence in the same organ, the organs
where recurrence was most common were lacrimal gland,
pancreas and thyroid glands [82]. Following a successful
induction treatment, especially some patients with high risk
benefited from maintenance treatment [83]. According to
international consensus guide, a steroid sparing agent may
be administered during maintenance treatment [81]. AZA,
MMF, methotrexate, tacrolimus and cyclophosphamide
are used as steroid sparing agents [84]. However, there is
no agreement on duration of treatment. As active IgG4RD cases with marked lymphoplasmacytic infiltrationare
more likely to respond to pharmacological treatment, in
this case the experts recommend immunosuppression.
Conversely, in long term stage fibrotic lesions, surgicaldebulking should be considered, as they respond poorly
to immunomodulatory agents [81]. Spontaneous or at
least temporary remissions have been reported [85].
Nevertheless, metachronous nature of the disease suggests
that although it may appear to improve transiently in an
organ, it may emerge again in a different region month
or years later [86]. According to the data obtained in
retrospective studies, RTX treatment was effective in cases
in which conventional steroid sparing agents were not
successful [87]. In patients who are on a steroid regimen
when RTX is instituted, the dose of steroid may be reduced
following RTX administration [88]. RTX is suitable for
maintenance treatment, but the optimal frequency and
duration of treatment still remains unclear. Bortezomib (a
protease inhibitor) has been used in addition to steroids
in recurrent IgG4-RLD [89]. Other biologics, including
infliximab, abatacept and tocilizumab, have been reported
to be effective in this condition but data are limited to
single case reports [90,91]. As described before, IgG4RD is a fibroinflammatory condition in which delays in
treatment can lead to significant fibrosis and damage.
4.1. Prognosis-IgG4-related malignancies
The outlook of IgG4-RD depends on the organs involved
and the severity of fibrosis. It is known that both

hematological and solid organ malignancy risk increases
in chronic inflammation, as can be seen in stomach cancer
caused by H. Pylori and hepatocellular cancer caused by
hepatic viruses. Drawing upon this relation, it may be
suggested that there may be a close correlation between
IgG4-RD and cancer. In IgG4-RD, the most common
hematological and solid organ malignancies are diffuse
large cell lymphoma and pancreatic cancer respectively.
Considering that IgG4-RD is preponderant in subjects
population, who are more immunocompromised, it
can be considered as a risk factor for both disease and
susceptibility to malignancy. Malignancy may occur
before, during or after IgG4-RD. In the study of Asano et
al. 158 patients diagnosed with IgG4-RD were followed for
a mean of 5.95 ± 4.48 years and malignancy was found in
34 of these patients [92], demonstrating that cumulative
risk of cancer was higher than that of general Japanese
population, with risk being the highest within the first
year. In the same study, malignancy was simultaneously
diagnosed with IgG4-RD in 12 patients [93]. High serum
total IgG, IgG4, SIL-2R (soluble interleukin 2 receptor)
and CIC (circulating immune complex) levels pointed
to increased risk of malignancy. In the aforementioned
study, 8 patients with malignancy achieved cure with
chemotherapy and radiotherapy while remission was
obtained in IgG4-RD as well, and they did not recur at
follow up evaluations [92]. Therefore, it was thought that
IgG4-RD may be a paraneoplastic condition. Yamamoto et
al. reported that among 105 patients with IgG4-RD the risk
of malignancy was increased in comparison to the general
population [93]. Shikawo et al. found the same result in
108 patients with AIP [94]. However, Hart et al. did not
find any significant increase in the risk of malignancy in
116 patients with type 1 AIP, as compared to 344 control
patients [95]. Likewise, in the study of Hirano et al. on 113
patients with IgG4-RD, malignancy risk was not increased
[96]. They attributed this result to the exclusion of patients
who had coexistent malignancies at the time of diagnosis.
Given the results of aforementioned studies, the relation
between malignancies and IgG4-RD is controversial.
5. Conclusion
The aim of the present review was to present a general
overview on clinical presentations, physiopathology
and treatment of IgG4-RD. As IgG4-RD is a relatively
new entity the etiology, prevalence and epidemiologic
knowledge is quite limited. Although the clinical picture
of the disease varies according to the involved organs,
compressive symptoms are common due to the tumefactive
nature of the disease. IgG4-RD is diagnosed based on the
combination of clinical, radiological and histopathological
findings. Typical histopathological features include
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storiform fibrosis, dense lymphoplasmacytic infiltrates
and obliterative phlebitis. Serum IgG4 level is neither
specific nor sensitive marker for IgG4-RD, but high
values have been found to correlate with the severity
and recurrence of disease. Glucocorticoids lead to rapid
clinical response in most IgG4-RD patients regardless of
the clinical picture and organ involvement. For patients
requiring treatment, prednisone is usually recommended
at an initial dose of 0.6 mg/kg/day (typically 30–40 mg/
day). In maintenance treatment, steroid-sparing agents
are used both to reduce cumulative risks of steroids and
to decrease risk of recurrence. Although association is not

clear, malignancies are frequently reported in IgG4-RD
patients. Therefore, it is prudent to monitor patients for
the symptoms of malignant diseases.
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